Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07126561) titled 'Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers' on Aug. 11.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of Chicago
Condition:
HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
Intervention:
Drug: Trastuzumab Deruxtecan
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 1, 2025
Target Sample Size: 43
To know more, visit https://clinic...